16 Major Drugs Subject To Re-pricing In Japan
This article was originally published in PharmAsia News
Executive Summary
Japan’s Central Social Medical Insurance Agency Jan. 25 has listed 16 drugs for re-pricing, including Eisai’s Aricept, Pfizer’s Lyrica, and Chugai’s Avastin.